An individual development theme involving joint research with the University of Tokyo and Nagasaki University and an AMED project to verify the mechanism of action, efficacy and pharmacokinetics of ReproTight, a treatment candidate for osteogenesis imperfecta, while also pursuing partnerships with pharmaceutical companies.